2025-10-04 - Analysis Report
Okay, let's break down the analysis of Natera Inc. (NTRA) based on the data provided.

**Report on Natera Inc. (NTRA)**

**0. Executive Summary**

Natera Inc. (NTRA) is a genetic testing company focused on reproductive health, cancer, and organ health. While NTRA has shown periods of strong growth and innovation, its recent performance has been volatile and underperforming the S&P 500. Positive news catalysts and strong analyst ratings provide some optimism, but financial metrics and market indicators suggest caution.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** NTRA
*   **Company:** Natera Inc.
*   **Description:** A genetic testing company focused on reproductive health, cancer, and organ health.
*   **NTRA Cumulative Return:** 72.99%
*   **VOO Cumulative Return:** 98.77%
*   **Relative Deviation:**
    *   Current: -33.1
    *   Max: 174.8
    *   Min: -88.5
    *   Relative Deviation (%): 21.0

**Analysis:** NTRA has significantly underperformed the S&P 500 over the tracked period. The current relative deviation of -33.1 indicates that NTRA is lagging behind the benchmark. The relative deviation percentage of 21.0 suggests that the current deviation is at the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha    | Beta    | Cap(B) |
|------------|--------|--------|----------|---------|--------|
| 2015-2017  | -10.0% | 70.1%  | -34.0%   | -0.2    | 1.2    |
| 2016-2018  | 22.0%  | 80.0%  | 6.0%     | 0.1     | 1.9    |
| 2017-2019  | 50.0%  | 80.0%  | 28.0%    | 1.0     | 4.6    |
| 2018-2020  | 186.0% | 80.5%  | 163.0%   | 1.1     | 13.7   |
| 2019-2021  | 96.0%  | 80.5%  | 49.0%    | 1.6     | 12.8   |
| 2020-2022  | -77.0% | 80.5%  | -76.0%   | 0.1     | 5.5    |
| 2021-2023  | -194.0%| 76.6%  | -195.0%  | -1.1    | 8.6    |
| 2022-2024  | 8.0%   | 76.6%  | -13.0%   | -1.2    | 21.7   |
| 2023-2025  | 100.0% | 76.6%  | 37.0%    | 0.1     | 23.0   |

*   **CAGR:** Fluctuates significantly, indicating high volatility.
*   **MDD:** Consistently high, suggesting substantial drawdowns.
*   **Alpha:** Shows periods of outperformance (positive Alpha) and underperformance (negative Alpha) relative to the benchmark. Recent years show significant underperformance.
*   **Beta:** Varies, indicating different levels of correlation with the market.

**2. Recent Price Action**

*   **Current Price:** 167.35
*   **Last Market Data:**
    *   Price: 167.35
    *   Previous Close: 160.21
    *   Change: 4.46
*   **Moving Averages:**
    *   5-day MA: 162.13
    *   20-day MA: 169.37
    *   60-day MA: 158.00

**Analysis:** The current price is above the 5-day and 60-day moving averages but below the 20-day moving average. The positive change of 4.46 from the previous close suggests a recent upward price movement.  The price jump suggests some short-term positive momentum.

**3. Market Risk Indicators**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 43.87 (Neutral)
*   **PPO:** -0.93 (Bearish)
*   **Hybrid Signal:** Buy 100% of cash (6 shares - Very Safe - MRI:0.90).
*   **Delta Relative Deviation (20-day):** -2.6 (Short-term Decline)
*   **Expected Return (%):** -179.7 (Long-Term Underperformance)

**Analysis:**

*   The MRI indicates a high investment recommendation.
*   The RSI is neutral, suggesting the stock is neither overbought nor oversold.
*   The negative PPO suggests a bearish trend.
*   The Hybrid Signal is indicating "Buy".
*   The negative delta relative deviation indicates recent underperformance relative to the benchmark.
*   The significantly negative expected return suggests potential underperformance compared to the S&P 500 over a long-term investment horizon.

**4. Recent News & Significant Events**

*   **Positive Catalysts:**
    *   Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT.
    *   Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer.
    *   Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging.
*   **Mixed/Neutral:**
    *   Exploring 3 High Growth Tech Stocks In The US Market.
    *   2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds.
    *   Stocks making big moves yesterday.

**Analysis:** The recent news highlights positive developments in Natera's product pipeline and validation studies, which could act as positive catalysts for the stock.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~1.53)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 193.21 / 235.00 / 37.00

**Analysis:** Analyst consensus is "Buy" with a significant number of opinions. The average target price suggests potential upside, but the wide range (37.00 to 235.00) reflects uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.5  | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2024-08-09 | -0.3  | 0.41 B$    |
| 2025-08-08 | -0.3  | 0.41 B$    |

**Analysis:**

*   Natera has consistently reported negative EPS, indicating losses.
*   Revenue has generally been increasing, but profitability remains a concern.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.55B    | 63.41%        |
| 2025-03-31 | $0.50B    | 63.12%        |
| 2024-12-31 | $0.48B    | 62.94%        |
| 2024-09-30 | $0.44B    | 61.79%        |
| 2024-06-30 | $0.41B    | 58.83%        |

Capital and Profitability:

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $1.25B    | -8.10%    |
| 2025-03-31 | $1.24B    | -5.40%    |
| 2024-12-31 | $1.20B    | -4.50%    |
| 2024-09-30 | $0.88B    | -3.60%    |
| 2024-06-30 | $0.84B    | -4.48%    |

**Analysis:**

*   Revenue is growing consistently.
*   Profit margins are healthy.
*   Equity is increasing.
*   ROE is negative, reflecting the losses despite the increased equity.

**7. Overall Analysis**

Natera presents a mixed picture.

*   **Positives:**
    *   Strong revenue growth and healthy profit margins.
    *   Positive news catalysts from product developments and validation studies.
    *   Strong analyst consensus with upside potential based on target prices.
    *   High MRI indicating favorable investment conditions.
*   **Negatives:**
    *   Significant underperformance relative to the S&P 500.
    *   Consistently negative EPS and negative ROE, indicating ongoing losses.
    *   High historical volatility and significant drawdowns.
    *   Bearish PPO and negative long-term expected return.

**Conclusion:**

While the positive news and analyst sentiment are encouraging, the underperformance, negative profitability metrics, and long-term underperformance expectations warrant caution. Investors should carefully weigh the potential risks and rewards before investing in NTRA. Monitoring future earnings reports and progress on profitability will be crucial.
